Esprit Holdings Limited (ESPGY)

Inozyme Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 8, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	36	48	147	305	258	275
Market Cap Growth	-58.41%	-67.22%	-51.88%	18.32%	-6.18%	34.49%
Enterprise Value	41	83	233	288	287	428
Last Close Price	0.02	0.04	0.11	0.22	0.18	0.27
PE Ratio	-	-	-	-	5.28	-
PS Ratio	6.60	8.90	22.93	0.34	0.24	0.43
PB Ratio	1.57	2.11	0.58	0.56	0.39	0.50
P/TBV Ratio	-	-	1.71	0.90	0.59	0.90
P/FCF Ratio	3.65	4.92	-	21.05	3.90	163.86
P/OCF Ratio	3.30	4.45	-	11.95	3.59	29.18
EV/Sales Ratio	7.65	15.42	36.45	0.32	0.27	0.66
EV/EBITDA Ratio	2.07	-	-	-	8.80	-
EV/EBIT Ratio	-	-	-	-	22.14	-
EV/FCF Ratio	4.18	8.52	-	19.84	4.34	255.25
Debt / Equity Ratio	0.71	0.71	0.99	0.49	0.51	0.72
Debt / EBITDA Ratio	0.81	0.81	4.05	-	3.31	-
Debt / FCF Ratio	1.65	1.65	-	18.16	5.11	235.77
Asset Turnover	0.01	0.01	0.01	0.76	0.82	-
Inventory Turnover	-	-	0.01	2.64	3.17	-
Quick Ratio	1.18	1.18	0.45	1.09	1.45	0.90
Current Ratio	1.44	1.44	1.04	1.91	2.23	1.45
Return on Equity (ROE)	-26.78%	-26.78%	-6.87%	-14.20%	8.14%	-
Return on Assets (ROA)	-1.03%	-1.03%	-1.73%	-5.70%	0.62%	-
Return on Capital (ROIC)	-1.51%	-1.51%	-2.45%	-7.60%	0.84%	-
Return on Capital Employed (ROCE)	-	-	-	-	1.30%	-
Earnings Yield	-442.47%	-328.35%	-204.00%	-27.92%	18.95%	-191.30%
FCF Yield	27.41%	20.34%	-78.93%	4.75%	25.62%	0.61%
Buyback Yield / Dilution	-	-	-	-9.05%	-	-
Total Shareholder Return	-	-	-	-9.05%	-	-

Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.